文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

感染性休克患者早期辅助使用亚甲蓝:一项随机对照试验

Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial.
PubMed 文献 · Crit Care · 2023-03-13
一句话结论感染性休克24小时内启动亚甲蓝可缩短血管加压药停药时间(69 h vs 94 h,p<0.001),不增加不良事件。

本单中心随机对照试验纳入91例符合Sepsis-3标准的感染性休克患者,45例接受亚甲蓝、46例接受安慰剂,评估早期辅助亚甲蓝能否缩短28天时血管加压药停药时间。结果显示亚甲蓝组停药时间更短(69 h vs 94 h,p<0.001),28天无血管加压药天数多1天(p=0.008),ICU住院缩短1.5天(p=0.039),总住院缩短2.7天(p=0.027);机械通气天数与死亡率相似,无与亚甲蓝相关的严重不良事件。作者认为该结果支持在更大规模随机临床试验中进一步研究亚甲蓝。

要点

  • 感染性休克24小时内启动亚甲蓝,血管加压药停药时间69 h vs 安慰剂94 h(p<0.001)。
  • 28天无血管加压药天数亚甲蓝组多1天(p=0.008)。
  • ICU住院缩短1.5天(p=0.039)、总住院缩短2.7天(p=0.027)。
  • 机械通气天数与28天死亡率两组相似,无与亚甲蓝相关的严重不良事件。
  • 作者认为该单中心结果支持在更大规模随机临床试验中进一步研究亚甲蓝。

适用人群与场景

  • 符合Sepsis-3标准的感染性休克患者,在单中心随机对照试验中随机分配至亚甲蓝或安慰剂组。

诊断标准与关键阈值

  • 感染性休克诊断依据Sepsis-3标准。

处置流程与药物剂量

  • 亚甲蓝作为早期辅助治疗,在感染性休克患者中于24小时内启动;原文未报告具体剂量、给药途径与频次。

研究设计与关键结果

  • 单中心随机对照试验,共91例随机患者,亚甲蓝组45例、安慰剂组46例。
  • 主要终点28天血管加压药停药时间:亚甲蓝组69 h(IQR 59-83)vs 安慰剂组94 h(IQR 74-141),p<0.001。
  • 次要终点28天无血管加压药天数:亚甲蓝组较对照组多1天(p=0.008)。
  • 次要终点ICU住院时间:亚甲蓝组较对照组缩短1.5天(p=0.039)。
  • 次要终点总住院时间:亚甲蓝组较对照组缩短2.7天(p=0.027)。
  • 机械通气天数与死亡率两组相似。
  • 无与亚甲蓝给药相关的严重不良事件。

证据类型、等级与局限

  • 证据类型:单中心随机对照试验。
  • 作者结论:支持在更大规模随机临床试验中进一步研究亚甲蓝。
  • 试验注册:ClinicalTrials.gov注册号NCT04446871,2020年6月25日回顾性注册。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在感染性休克患者中于24小时内启动亚甲蓝可缩短血管加压药停药时间、增加28天无血管加压药天数,并缩短ICU与住院时间,且无不良事件;作者支持在更大规模随机临床试验中进一步研究亚甲蓝。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Methylene blue (MB) has been tested as a rescue therapy for patients with refractory septic shock. However, there is a lack of evidence on MB as an adjuvant therapy, its' optimal timing, dosing and safety profile. We aimed to assess whether early adjunctive MB can reduce time to vasopressor discontinuation in patients with septic shock.

METHODS: In this single-center randomized controlled trial, we assigned patients with septic shock according to Sepsis-3 criteria to MB or placebo. Primary outcome was time to vasopressor discontinuation at 28 days. Secondary outcomes included vasopressor-free days at 28 days, days on mechanical ventilator, length of stay in ICU and hospital, and mortality at 28 days.

RESULTS: Among 91 randomized patients, forty-five were assigned to MB and 46 to placebo. The MB group had a shorter time to vasopressor discontinuation (69 h [IQR 59-83] vs 94 h [IQR 74-141]; p < 0.001), one more day of vasopressor-free days at day 28 (p = 0.008), a shorter ICU length of stay by 1.5 days (p = 0.039) and shorter hospital length of stay by 2.7 days (p = 0.027) compared to patients in the control group. Days on mechanical ventilator and mortality were similar. There were no serious adverse effects related to MB administration.

CONCLUSION: In patients with septic shock, MB initiated within 24 h reduced time to vasopressor discontinuation and increased vasopressor-free days at 28 days. It also reduced length of stay in ICU and hospital without adverse effects. Our study supports further research regarding MB in larger randomized clinical trials. Trial registration ClinicalTrials.gov registration number NCT04446871 , June 25, 2020, retrospectively registered.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Ibarra-Estrada M, Kattan E, Aguilera-González P, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023. PMID: 36915146. doi:10.1186/s13054-023-04397-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。